BidaskClub has broken shares of Nabriva Therapeutics (NASDAQ: NBRV) from a sales scale to a strong sales scale in a report published on Thursday.
A number of other equity research analysts have also commented on the company recently. Morgan Stanley began broadcasting on Nabriva Therapeutics in a research note on Friday, September 7th. They gave the company a weight score and a price target of $ 8.00. The Nabriva Therapeutics Zacks Investment Research rose from a scale to buy scale and set a price target of $ 3.75 to the company in a research note on Wednesday, July 18th. Bank of America set a $ 5.00 price target on Nabriva Therapeutics and gave the company a scale in a research note on Monday, August 27th. Needham and Company LLC re-published a purchase grade and issued a price target of $ 18.00 on shares of Nabriva Therapeutics in a research note on Wednesday, July 25th. Finally, ValuEngine Therapeutics Nabriva rose from a scale to buy in a research note on Thursday, 1st November. One equity research analyst has rated the stock with a sales scale, one has given a drop rate and eight have announced a purchase rating for the company's stock. The stock currently has a consensus rate of Purchase and a consensus target price of $ 10.17.
NASDAQ NBRV shares had traded $ 0.05 during trading hours on Thursday, hitting $ 2.05. The stock had a volume of 240,183 trading shares, compared to an average of 408,023. Nabriva Therapeutics has a 52 week low of $ 1.84 and 52 weeks high of $ 6.94. The company has a debt-to-equity ratio of 0.01, an current ratio of 7.35 and a fast ratio of 7.35.
Cattle funds and other institutional investors have recently made changes to their stock jobs. Councilors of the LP's Dimensional Fund offered its holdings at Nabriva Therapeutics by 207.6% in the second quarter. LP Dimensional Fund Advisers now own 344,061 shares of the biotechnology company worth $ 1,197,000 after purchasing additional 232,196 shares during the last quarter. Wedbush Securities Inc. received a new investment in Nabriva Therapeutics in the second quarter worth about $ 371,000. Clear Harbor Asset Management LLC raised its holdings at Nabriva Therapeutics by 1,195.7% in the 3rd quarter. Clear Harbor Asset Management LLC now owns 212,500 shares of the company's biotechnology value of $ 443,000 after purchasing 196,100 additional shares during the last quarter. Prosight Management LP raised its holdings at Nabriva Therapeutics by 73.6% in the second quarter. Prosight Management LP now owns 421,414 shares of the biotechnology company worth $ 1,467,000 after the purchase of 178,725 additional shares during the last quarter. Finally, BlackRock Inc. his holdings at Nabriva Therapeutics by 154.0% in the first quarter. BlackRock Inc. now owns 453,064 stock shares of the biotechnology company worth $ 2,278,000 after buying 274,709 additional shares during the last quarter. Organizational investors and hedge funds have 3.20% of stock.
Therapeutic Nabriva Company Profile
Nabriva Therapeutics plc, a clinical biopharmaceutical company, undertakes the research and development of anti-infectious agents to treat infections among people. The company focuses on the pleuromutilin class of antibiotics. Its main increase is lefamulin, which is in the Phase III clinical prototypes in intravenous and oral formulations for the treatment of community-acquired bacteria pneumonia; and has completed Phase II clinical trials for acute infection of acute bacterial skin structure.
Recommended Story: Final Funds Closed
Receive News and Minutes for Nabriva Daily Therapeutics – Enter your email address below for a summary daily summary of the latest news and analysts for Nabriva Therapeutics and related companies with the FREE daily email newsletter MarketBeat.com.